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Summary:  When used as pre-travel malaria chemoprophylaxis to enable a ‘drug-free holiday’, 
the 3-day atovaquone/proguanil schedule (250mg/100mg, 4 tablets/day for 3 consecutive days) 
had a high compliance rate of 97.7%, and was well tolerated and accepted by travellers.  
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Abstract 
Background: Poor compliance with chemoprophylaxis is a major contributing factor to the risk 
of malaria in travellers. Pre-travel chemoprophylaxis may improve compliance by enabling 
‘drug-free holidays’. The standard treatment dose of atovaquone/proguanil (250mg/100mg, 4 
tablets/day for 3 days) provides protection against malaria for at least 4 weeks, and could 
therefore potentially be used for pre-travel chemoprophylaxis. In this study, we assessed the 
compliance, tolerability, and acceptability of the 3-day atovaquone/proguanil schedule for 
malarial chemoprophylaxis. 
Methods: 233 participants were recruited from four specialised travel medicine clinics in 
Australia. Adults travelling to malaria-endemic areas with low/medium risk for ≤4 weeks were 
enrolled, and prescribed the 3-day schedule of atovaquone/proguanil, completed at least one day 
before departure. Questionnaires were used to collect data on demographics, travel destination, 
medication compliance, side effects, and reasons for choosing the 3-day schedule. The study 
was registered with the Australian and New Zealand Clinical Trials Registry, number 
ACTRN12616000640404 
Results: Overall, 97.7% of participants complied with the 3-day schedule. Although side effects 
were reported in 43.3% of the participants, these were well tolerated, and mainly occurred 
during the first and second day. None of the participants developed malaria. The main reasons 
for choosing the 3-day schedule over standard chemoprophylaxis options were that it was easier 
to remember (72.1%), required taking fewer tablets (54.0%), and to help scientific research 
(54.0%).  
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Conclusions: The 3-day atovaquone/proguanil schedule had an impressively high compliance 
rate, and was well tolerated and accepted by travellers. Further studies are required to assess the 
effectiveness of this schedule for chemoprophylaxis in travellers. 
Keywords: malaria, chemoprophylaxis, atovaquone, proguanil, travel  
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Introduction 
Malaria is an important cause of severe illness and preventable deaths in travellers [1,2].  
An estimated 30,000 cases of travel-related malaria are reported annually [1]. In a study of 
~7000 returned travellers with fever at GeoSentinel clinics, malaria was the most common 
diagnosis, accounting for 21% of cases and 33% of fatalities [3].  The mainstay of malaria 
prevention in travellers is the use of chemoprophylactic medications; a number of effective 
drugs are available and currently recommended schedules involve taking medications before, 
during, and after travel to a malaria-endemic area [4]. Atovaquone/proguanil is one of three 
commonly prescribed medications for chemoprophylaxis; the standard adult dosage is one tablet 
(250mg/100mg) per day, starting 1-2 days before arriving in a malaria-endemic area, and 
continuing daily until 7 days after leaving [4]. The other two commonly used medications are 
doxycycline (adult dose 100mg/day, starting 1-2 days before arriving in a malaria-endemic area, 
and continuing until 4 weeks after leaving) and mefloquine (adult dose 250mg/week, starting at 
least 2 weeks before arriving in a malaria-endemic area, and continuing until 4 weeks 
afterwards) [4]. 
Although effective medications are available for malaria chemoprophylaxis, their 
effectiveness is often compromised by poor compliance [5].
  
Most cases of travel-related malaria 
are associated with poor compliance or complete failure to take chemoprophylaxis. Studies 
around the world have found poor compliance amongst the full spectrum of travellers including 
tourists [6], backpackers [7], expatriate workers [8,9], military personnel [10-12], volunteers 
[13] and those returning to home countries to visit friends and relatives (VFR) [14]. A study of 
imported malaria in Australia found that of 246 cases, only 56% took chemoprophylaxis, and of 
these only 29% were fully compliant [15]. Failure to take chemoprophylaxis and poor 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy854/5114398 by Library user on 31 O
ctober 2018
 5 
 
compliance have also been associated with an increased risk of severe malaria and malaria-
related deaths [16-18]. 
Improving compliance with malaria chemoprophylaxis could therefore significantly 
reduce the risk of travel-related malaria and deaths. Poor compliance is at least partly due to the 
need to take medications for long periods of time.  Multiple studies have found that forgetting to 
take medications was a common problem [19,20], so compliance could potentially be improved 
by using simpler medication schedules, such as shorter duration, less doses, or schedules that 
can be completed before travel [5,21].  In 2007, a group of travel medicine and malaria experts 
highlighted the need to explore pre-travel malaria chemoprophylaxis regimens, or ‘drug-free 
holidays’, to improve compliance [5].  However, little progress has been made in the past 
decade.    
Atovaquone/proguanil is highly effective for treating malaria when given at a dose of 
1000mg/400mg (4 tablets) per day for 3 consecutive days (referred to henceforth as the 3-day 
schedule). In malaria intervention studies, atovaquone/proguanil has been used to treat any pre-
existing malaria in the participants. In this setting, studies showed that the 3-day schedule 
provided protection against malaria for >4 weeks even in highly endemic areas [22,23]. Studies 
in volunteers in controlled environments in non-endemic countries have shown similar results 
[24,25]. Considering that the elimination half lives of atovaquone and proguanil are 2-3 days 
and 14-20 hours, respectively, the lengthy antimalarial activity cannot be explained by simple 
pharmacokinetics, and is likely to be attributed to the causal prophylactic effect of the drugs on 
parasites in the liver [5]. A summary of the evidence for atovaquone/proguanil’s extended 
antimalarial activity, and therefore the rationale for its use in chemoprophylaxis, is provided in 
Table S1. 
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The 3-day schedule’s extended antimalarial activity could potentially allow it to be used 
for prophylaxis, and the short duration of medications (3 days) might improve compliance in 
travellers. For trips of <4 weeks, travellers could complete the 3-day schedule prior to travel, 
and have a “drug-free holiday” [5]. For longer trips, the 3-day schedule could be repeated every 
4 weeks to provide longer protection. For travellers spending more than three days in a malaria 
endemic area, the 3-day schedule is also cheaper than the standard daily schedule for 
atovaquone/proguanil. Other advantages include the ability to manage any side effects before 
departure (by changing to the standard schedule or different medication), avoiding the problem 
of not being able to swallow or absorb medications in case of gastrointestinal illness during 
travel, and avoiding the need to carry or buy medications overseas.  
Atovaquone/proguanil is safe and well tolerated as prophylaxis in healthy travellers (1 
tablet/day), and as treatment for malaria (4 tablets/day) [26-29]. However, tolerability of the 3-
day schedule has not been assessed in the prophylaxis setting, when travellers are usually well, 
and milder side effects might be more be apparent.  In this study, we investigated the 
compliance, tolerability and acceptability of the 3-day atovaquone/proguanil schedule for pre-
travel malaria chemoprophylaxis.  
 
Methods 
Study design 
A single-arm trial was conducted to assess the compliance, tolerability, and acceptability 
of a 3-day atovaquone/proguanil schedule. Four specialist travel medicine clinics from the 
Travel Medicine Alliance group in Australia participated: Dr Deb – The Travel Doctor, 
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Brisbane; Travel-Bug Vaccination Clinic, Adelaide; Health HQ, Gold Coast; and Travel 
Medicine Centre Perth.  
 
Study population 
Adults (≥18 years) travelling to malaria-endemic areas in Asia, Pacific Islands, and 
South/Central America for ≤4 weeks were eligible. Exclusion criteria included taking 
medications that interact with atovaquone/proguanil (metoclopramide, rifampicin, 
tetracyclines,fluvoxamine); pregnancy or planning pregnancy; significant medical conditions 
(i.e. diabetes, heart diseases, asthma, epilepsy, depression, renal or liver impairment, 
gastrointestinal disorders); and taking long-term antibiotics. Considering that our study was 
focused on assessing compliance, tolerability and acceptability (and not effectiveness), travellers 
to sub-Saharan Africa were excluded from the study because of the higher risk of malaria 
compared to other regions [1,30]. 
 Travellers who required malaria prophylaxis were given the options of standard 
schedules of doxycycline, mefloquine, and atovaquone/proguanil, as well as the 3-day 
atovaquone/proguanil schedule.  Choice of prophylaxis was based on multiple factors including 
time to departure, duration and side effects of the medications, daily versus weekly dosing, co-
morbidities, and personal preference.  Pros and cons of options were explained to potential 
participants, including the ‘off-label’ use of the 3-day schedule for prophylaxis. Cost was also 
discussed, and travellers or their employers paid for medications regardless of which option was 
chosen.  All travellers who chose the 3-day schedule were enrolled in the study.  
 
Sample size 
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Sample size was calculated to identify any differences in the prevalence of adverse 
reactions with the 3-day schedule in a prophylaxis setting, compared to reported adverse 
reactions for the standard prophylaxis dose, or the 3-day schedule when used for treatment [26]. 
Assuming a baseline prevalence of gastrointestinal side effects of up to 15% (i.e. diarrhoea, 
nausea, and abdominal pain) [26], 200 participants would be required to provide 90% power at a 
type I error of 0.05 to detect a 10% difference between groups. Assuming withdrawal or loss to 
follow-up of 10%, the study aimed for a target sample size of 220. 
 
Informed Consent and Approvals 
Information sheets were provided to all participants, and written informed consent was 
obtained before enrolment.  The study was approved by the Australian National University 
Human Research Ethics Committee (2016/295), and registered with the Australian and New 
Zealand Clinical Trials Registry (ACTRN12616000640404). 
 
Study intervention and data collection 
Participants were instructed to take 4 tablets of atovaquone/proguanil (250mg/100mg) 
per day (taken all at once) for 3 consecutive days, with the last dose taken at least one day before 
travel.  Participants were encouraged to take each dose with a fatty meal (>24g) as there is 
evidence that dietary fat increases the absorption of atovaquone [31] and decreases the 
likelihood of gastrointestinal side effects. 
Participants were asked to contact their clinic if they were unable to tolerate any of the 
doses, or if side effects were debilitating and they did not wish to continue. For these 
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participants, a doctor or nurse discussed alternative chemoprophylaxis regimens to ensure 
adequate protection against malaria.   
 Data were collected using three questionnaires, and a memory aid and symptom diary: 
1. A travel medicine nurse completed an enrolment questionnaire with each participant. 
Information was collected on the current trip, previous history of malaria, travel to malaria 
endemic areas in the previous 12 months, previous experience with taking anti-malarial 
medications, past medical history, current medications and allergies.  
2. A nurse telephoned the participants and completed a pre-travel questionnaire the day 
after the 3-day schedule was completed. The nurse confirmed whether the 3-day schedule was 
taken correctly and documented any side effects during and immediately after the schedule. 
3. Within a week after return to Australia, a nurse telephoned the participants to 
complete a post-trip questionnaire, to collect information on any adverse reactions or diagnosis 
of malaria during or after travel. Participants were advised to contact the clinic if they were 
diagnosed with malaria after the post-travel questionnaire. 
4.  A Memory Aid and Symptom Diary was provided to record any symptoms and their 
intensity for 10 days after starting the 3-day schedule.  Symptom severity was defined as mild, 
moderate, or severe based on the following criteria: 
 Vomiting: 1-2 episodes in 24 hours; >2 episodes in 24 hours; required intravenous 
hydration 
 Diarrhoea: 2-3 loose stools; 4-5 loose stools; 6 or more loose stools in 24 hours 
 Mouth ulcers:  Easily tolerated, able to eat and drink normally; discomfort, interfered 
with eating and drinking; incapacitating, great difficulty with eating and drinking 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy854/5114398 by Library user on 31 O
ctober 2018
 10 
 
 Other symptoms:  Easily tolerated, able to continue with normal activities; discomfort, 
interfered with normal daily activities; incapacitating, prevented normal activities. 
 
Statistical analysis 
  All participants who started the 3-day schedule were included in the analysis. 
Descriptive statistics were used to report the characteristics of the participants. The outcomes 
(compliance, tolerability, acceptability) were estimated as the proportion of participants who 
completed the 3-days schedule and reported each outcome over the total number of participants 
who responded to the pre-travel questionnaire. 
Multivariate logistic regression models were built to identify independent predictors of 
overall side effects, and specific side effects that were reported in >10% of participants. 
Predictor variables were defined a priori and included gender, age, comorbidities, allergies, 
taking atovaquone/proguanil with high-fat foods, and prior use of atovaquone/proguanil and/or 
other antimalarials. Predictor variables were entered using a stepwise forward selection in the 
regression models. All tests were two-tailed and p-value of <0.05 was deemed statistically 
significant. Analyses were conducted using Stata MP version 14 (StataCorp, College Station, 
TX, USA). 
 
Results 
Characteristics of the participants 
A total of 233 participants were enrolled in the study from August 2016 to January 2018, 
of whom 215 (92.3%) completed the enrolment and pre-travel questionnaires, and were included 
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in the analysis. After return from their travels, 205 participants were successfully followed-up 
(Figure 1). No participants reported diagnosis of malaria while overseas or upon return.  
Median age of participants was 43.8 (interquartile range [IQR] 28.9-57.8) years and 
51.2% were female. Twenty-one participants (9.8%) reported a comorbidity, most commonly 
asthma (4.7%) and gastrointestinal diseases (3.3%). The majority of the participants reported 
previous travel to malaria-endemic countries (65.6%) and use of antimalarial medications 
(50.7%). Sixty-six participants (30.7%) reported previous use of atovaquone/proguanil and only 
three had previously experienced side effects to the medication (i.e. nausea in all three 
participants, diarrhoea and abdominal pain in one participant, and vomiting in another 
participant). Countries of destination included India, Cambodia, Vietnam, Papua New Guinea, 
Laos, Myanmar, Indonesia, Thailand, East Timor, Malaysia, Solomon Islands, Brazil, and 
Ecuador. The main reasons for choosing the 3-day schedule were that it was easier to remember 
(72.1%), required taking fewer tablets (54.0%), and to help scientific research (54.0%) (Table 
1).  
 
Compliance 
The 3-day schedule was correctly completed by 210 of 215 participants (97.7%, 95% CI 
94.7-99.2%). Two did not complete the schedule due to gastrointestinal side effects (diarrhoea, 
nausea, vomiting, or abdominal pain), two took the medication every second day or irregularly, 
while one discontinued because of an upper respiratory tract infection (Figure 1). 
 
Tolerability 
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Among those that completed the 3-day schedule, side effects were reported in 91 
participants (43.3%) (Figure 1); most commonly nausea (24.8%), diarrhoea (17.1%), tiredness 
(9.0%), headache (5.7%), and dizziness (5.7%). The prevalence of gastrointestinal side effects 
(33.8%) was higher than for the standard prophylaxis dose (15.9% [26], p-value <0.001), but 
similar to the 3-day schedule when used for treatment (40.5% [26], p-value = 0.13). Side effects 
were well tolerated, and interfered with their normal activities in only 3 (1.4%) participants. The 
majority of the side effects were mild (n=70, 33.3%), and only 10% of participants perceived the 
symptoms as moderate (n=16, 7.6%) or severe (n=5, 2.4%) (Figure 2 and S2). Side effects 
mainly occurred during the three days of the schedule (day 1 [25.7%], day 2 [27.6%], day 3 
[19.5%]), and rapidly improved thereafter (day 4 [1.9%], day 5 [0.5%]). All side effects resolved 
before departure (S2 and S3). Among those who reported side effects, median duration of 
symptoms was 2 ([IQR] 1-2) days. Three-quarters reported that symptoms lasted for 1 day 
(n=44, 48.3%) or 2 days (n=25, 27.5%). Only 20 (22.0%) and 2 (2.2%) reported symptoms that 
lasted for 3 and 4 days, respectively. No participants reported duration of symptoms exceeding 4 
days. 
Multivariate logistic regression models revealed that females had higher odds of 
developing overall side effects (odds ratio [OR], 1.79; 95% confidence interval [CI], 1.02-3.14) 
and nausea (OR, 2.09; 95%CI 1.07-4.08). Younger participants had higher odds of reporting 
nausea and the odds decreased by 21% (OR 0.79, 95%CI 0.64-0.97) per decade increase in age. 
No independent predictors were identified for diarrhoea (Table 2). 
 
Acceptability 
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After the trip, 196 participants (95.6%) responded that they would choose to take the 3-
day schedule again for future trips. Among the 9 (4.4%) participants who would not use the 3-
day schedule again, the main reason was that side effects were unacceptable (n=7) (Figure 1). 
 
 
Discussion 
Our study provides important data on the compliance, tolerability, and acceptability of 
the 3-day schedule of atovaquone/proguanil in healthy travellers, and the potential for using this 
schedule for malaria prophylaxis. The high compliance of (97.7%) is impressive compared to 
previous studies, which have reported 24-89% for the standard schedule of 
atovaquone/proguanil [29,32], 65-80% for proguanil [6,33], 60-79% for doxycycline [6,34], and 
68-80% for mefloquine [6,33,34]. Considering that poor compliance to chemoprophylaxis is a 
major contributing factor to travel-related malaria, the 3-day schedule has the potential to 
significantly reduce malaria in travellers.  
Although the 3-day schedule is known to be well tolerated when used to treat malaria, it 
is difficult to distinguish side effects (e.g. nausea, vomiting) from the symptoms of malaria.  Our 
study showed that 4 tablets/day is well tolerated in healthy travellers and the prevalence of 
reported side effects were similar to those reported when used for treatment [16]. The majority 
of side effects were mild, limited to 1-2 days duration, and completely resolved before 
departure.  
Our study also showed that the 3-day schedule was well accepted by travellers, with 
>95% indicating that they would choose this option again for future chemoprophylaxis. 
Travellers readily embraced the idea of ‘getting the malaria tablets out of the way before 
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departure’, or ‘not having to worry about malaria tablets if I am sick with diarrhoea and 
vomiting’. Further studies will be required to directly compare the compliance, acceptability and 
tolerability of the 3-day schedule against the standard atovaquone/proguanil prophylaxis 
schedule and its variations, including twice weekly dosage [35] or ceasing the medication one 
day after leaving a risk area [36].   
The standard prophylaxis dosage of atovaquone/proguanil is expensive compared to  
other anti-malarial medications, and can be prohibitively so for long trips. For a four week stay 
in a risk area, the cost difference between standard daily atovaquone/proguanil (~$194 for 37 
tablets) and the 3-day schedule (~$63 for 12 tablets) was ~AU$131 at the clinics where this 
study was conducted. 
The results should be considered in light of the study’s limitations. Compliance and 
acceptability were self-reported, and may be subject to participation bias.  However, our 
participants actively sought pre-travel health advice from specialist travel clinics and are 
generally motivated to take malaria chemoprophylaxis, so it is unlikely for this group to falsely 
report compliance.  Reports on side effects could have been influenced by recall bias, but this 
was minimised by use of a Memory Aid and Symptom Diary. We did not include a control 
group of travellers taking standard prophylaxis schedules of atovaquone/proguanil or other 
medications.  
No participant was diagnosed with malaria during or after travel, although the study was 
not designed to, nor has the statistical power to assess the effectiveness of the 3-day schedule for 
prophylaxis. Studies on populations in malaria endemic areas have provided compelling 
evidence that the 3-day schedule provides antimalarial activity for up to 5-6 weeks [22-25]. 
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However, further studies, including a larger sample size and higher risk destinations will be 
required to confirm effectiveness in non-immune travellers.  
In an experimental malaria challenge study, heavily infected mosquitoes were allowed to 
feed on six non-immune volunteers who were given atovaquone/proguanil 1000mg/400mg 7 
days earlier [37]. One developed parasitaemia 21 days post-challenge, but results were 
questionable because PCR and culture failed to confirm malaria. If the volunteer truly had 
parasitaemia, a single failure after such a severe challenge does not preclude the use of the 3-day 
schedule for prophylaxis, but signifies that like all other chemoprophylaxis, it is not 100% 
effective. The study also showed that chemoprophylaxis failure (in three volunteers, including 
two who used other schedules) was associated with poor absorption of atovaquone, and 
highlights the importance of taking the medications with a large (preferably fatty) meal [37]. 
Previous discussions on the long-lasting activity of atovaquone/proguanil raised 
concerns regarding development of drug resistance to atovaquone, because it has a longer half-
life and will be present after proguanil has been eliminated [22,24,25].  Atovaquone resistance 
might also be more likely with prolonged or repeated use, e.g. repeating the 3-day schedule 
every 4 weeks in long-term travellers. However, a recent study provided reassuring evidence 
that atovaquone-resistant parasites are unable to be transmitted by mosquitoes [22]. Also, drug 
pressure on atovaquone/proguanil created by travellers is unlikely differ significantly between 
the standard and 3-day schedules.   
In conclusion, our study showed that the 3-day schedule of atovaquone/proguanil is a 
promising option for malaria prophylaxis, with very high compliance rate, and was well 
tolerated and accepted by travellers. Further studies are required to assess effectiveness in non-
immune travellers. 
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Table 1. Participants’ characteristics 
 
Demographics 
 Female (%) 110 (51.2) 
 Median age (IQR) [range] 43.8 (28.9-57.8) [18.3-80.7] 
Medical history 
 Comorbidities (%) 21 (9.8) 
  Asthma (%) 10 (4.7) 
  Gastrointestinal diseases (%) 7 (3.3) 
  Cardiovascular diseases (%) 3 (1.4) 
  Depression (%) 3 (1.4) 
 Allergies to medications (%) 22 (10.2)* 
Prior exposure to malaria 
 Travelled to malaria endemic country (%) 141 (65.6) 
 Prior malaria infection (%) 6 (2.8) 
 Prior use of antimalarial medication (%) 109 (50.7) 
  Atovaquone/proguanil (%) 66 (30.7)†  
  Doxycycline (%) 50 (23.3) 
  Proguanil (%) 21 (9.8) 
  Mefloquine (%) 16 (7.4) 
  Chloroquine (%) 16 (7.4) 
Travel destination 
 India (%) 78 (36.3) 
 Cambodia (%) 34 (15.8) 
 Vietnam (%) 23 (10.7) 
 Laos (%) 19 (8.8) 
 Papua New Guinea (%) 17 (7.9) 
 Thailand (%) 17 (7.9) 
 Myanmar (%) 16 (7.4) 
 Malaysia (%) 12 (5.6) 
 Indonesia (%) 11 (5.1) 
 East Timor (%) 10 (4.7) 
 Solomon Islands (%) 4 (1.9) 
 Brazil (%) 3 (1.4) 
 Ecuador (%) 3 (1.4) 
Reason for choosing 3-day schedule 
 Easier to remember (%) 155 (72.1) 
 Requires fewer tablets (%) 116 (54.0) 
 Help scientific research (%) 116 (54.0) 
 Lower cost (%) 68 (31.6) 
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* Most common allergies were to penicillins and NSAIDs.  † Only 3 participants reported prior side effects. IQR 
interquartile range 
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Table 2. Univariate and multivariate logistic regression for predictors of side effects 
 
 Overall side effects Nausea Diarrhoea 
Univariate model 
OR (95%CI) 
Multivariate model 
OR (95%CI) 
Univariate model 
OR (95%CI) 
Multivariate model 
OR (95%CI) 
Univariate model 
OR (95%CI) 
Multivariate model 
OR (95%CI) 
Gender –Female 1.88 (1.08-3.27) 1.79 (1.02-3.14) 2.26 (1.18-4.33) 2.09 (1.07-4.08) 1.28 (0.62-2.63) - 
Age (per decade increase) 0.88 (0.74-1.05) 0.91 (0.76-1.08) 0.78 (0.63-0.95) 0.79 (0.64-0.97) 0.98 (0.78-1.22) - 
Presence of comorbidities 1.34 (0.53-3.39) - 0.74 (0.24-2.32) - 1.23 (0.39-3.94) 1.64 (0.56-4.84) 
Allergies to medications 1.50 (0.61-3.70) - 1.24 (0.46-3.40) - 1.59 (0.54-4.67) - 
Taking atovaquone/proguanil with high-fat foods 1.37 (0.77-2.45) - 1.68 (0.88-3.21) - 0.86 (0.39-1.86) - 
Prior use of antimalarial medication 0.90 (0.52-1.55) - 1.17 (0.62-2.19) - 0.73 (0.35-1.50) - 
Prior use of atovaquone/proguanil 0.95 (0.53-1.71) - 1.21 (0.62-2.36) 1.46 (0.73-2.91) 0.68 (0.30-1.55) 0.67 (0.30-1.53) 
OR odds ratio; CI confidence interval. Boldface data indicate statistically significant results 
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Figure legends 
 
Figure 1. Participants enrolment and follow-up flowchart  
 
Figure 2. Percentage of participants who reported side effects, stratified by intensity 
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Figure 1 
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Figure 2 
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